Related Experiment Video
Updated: Aug 10, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
[Candida infections in immunocompromised hosts]
Insights
Candida infections pose a significant challenge for immunocompromised patients, ranging from mild thrush to fatal candidemia. Early diagnosis and prompt treatment with systemic antifungals are crucial for managing these invasive fungal infections.
Area of Science:
- Mycology
- Infectious Diseases
- Immunology
Background:
- Immunocompromised patients face a rising incidence of Candida infections, presenting a spectrum from oral thrush to life-threatening candidemia.
- Invasive Candida infections in this population are associated with substantial mortality rates, highlighting the need for effective management strategies.
Discussion:
- Diagnosing Candida infections is complex, relying on clinical presentation, microbiological cultures, and histological analysis.
- Current treatment primarily involves systemic antifungal agents, including fluconazole, amphotericin B, itraconazole, voriconazole, and caspofungin.
Key Insights:
- The increasing prevalence of immunocompromised individuals directly correlates with a rise in invasive Candida infections.
- Accurate and timely diagnosis is critical due to the high mortality associated with invasive candidiasis.
Outlook:
- Empirical and prophylactic antifungal treatment is essential for selected high-risk patient groups.
- Further research into novel diagnostic and therapeutic approaches for Candida infections in immunocompromised hosts is warranted.
Abstract:
Candida infections in the immunocompromised patients represent a major therapeutic challenge. In immunocompromised host candidiasis can range from asymptomatic oral thrush to life-threatening candidemia. Invasive Candida infections parallel increase in the immunocompromised patient population and are characterized by high mortality. Diagnosis of Candida infections is difficult and is based on clinical picture, microbiological and histological examinations. Mainstay of treatment are systemic antimycotic agents (fluconazole, amphotericin B, itraconazole, voriconazole and caspofungin). Empirical and prophylactic treatment is warranted in selected groups of high risk patients.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Fungal Phylum Microsporidia
Cryptococcal Meningitis
Candidiasis

